



Comprehensive Review of Lung Cancer

AGENDA

Comprehensive Review of Lung Cancer San Antonio, TX—Saturday, September 22, 2007

8:30 AM	Welcome and Introductions	Chandra P. Belani, MD
	Multimodality Therapy, Adjuvant Therapy and Surgery	
	Session Chair: Chandra P. Belani, MD	
8:35 AM	Early Stage Non–Small-Cell Lung Cancer: Adjuvant and Neoadjuvant Therapy	Katherine Pisters, MD
9:05 AM	Management of Stage III Disease: Multimodality Therapy	Hak Choy, MD
9:35 AM	Staging the Mediastinum: Controversies and Consensus	TBD
10:05 AM	Screening for Lung Cancer: An Overview	Michael Liptay, MD
10:35 AM	Panel Discussion	
10:50 AM	Break	
	Targeting Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor in Lung Cancer	
	Session Chair: Suresh Ramalingam, MD	
11:00 AM	Bevacizumab: Implications of Recent Data in Non–Small-Cell Lung Cancer	Howard (Jack) West, MD
11:30 AM	Small Molecule Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors and Multikinase Inhibitors	Anthony Tolcher, MD
12:00 PM	Clinical and Molecular Predictors for Targeting Epidermal Growth Factor Receptor	Ronald Natale, MD
12:30 PM	Lunch	
1:30 PM	Supportive Therapy for Lung Cancer Patients	Jeffrey Crawford, MD
2:00 PM	Panel Discussion	
	State of the Art and Other Targeted Agents in Non–Small-Cell Lung Cancer	
	Session Chair-Chandra P. Belani, MD	
2:15 PM	First-Line Chemotherapy Options in Advanced Disease	Chandra P. Belani, MD
2:45 PM	Second-line Chemotherapeutic Options for Non–Small-Cell Lung Cancer	Ramaswamy Govindan, MD
3:15 PM	Histone Deacetylase Inhibitors and Other Novel Agents in Lung Cancer	Suresh Ramalingam, MD
3:45 PM	Panel Discussion	
4:00 PM	Closing Remarks and Adjourn	Chandra P. Belani, MD